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Abstract: Rhinovirus is a common cause of upper and lower respiratory tract infections in adults,
especially among the elderly and immunocompromised. Nevertheless, its clinical characteristics and
mortality risks have not been well described. A retrospective analysis on a prospective cohort was
conducted in a single teaching hospital center over a one-year period. We compared adult patients
hospitalized for pneumonia caused by rhinovirus infection with those hospitalized for influenza
infection during the same period. All recruited patients were followed up for at least 3 months
up to 15 months. Independent risk factors associated with mortality for rhinovirus infection were
identified. Between 1 March 2014 and 28 February 2015, a total of 1946 patients were consecutively
included for analysis. Of these, 728 patients were hospitalized for rhinovirus infection and 1218
patients were hospitalized for influenza infection. Significantly more rhinovirus patients were elderly
home residents and had chronic lung diseases (p < 0.001), whereas more influenza patients had
previous stroke (p = 0.02); otherwise, there were no differences in the Charlson comorbidity indexes
between the two groups. More patients in the rhinovirus group developed pneumonia complications
(p = 0.03), required oxygen therapy, and had a longer hospitalization period (p < 0.001), whereas
more patients in the influenza virus group presented with fever (p < 0.001) and upper respiratory
tract symptoms of cough and sore throat (p < 0.001), and developed cardiovascular complications
(p < 0.001). The 30-day (p < 0.05), 90-day (p < 0.01), and 1-year (p < 0.01) mortality rate was significantly
higher in the rhinovirus group than the influenza virus group. Intensive care unit admission (odds
ratio (OR): 9.56; 95% confidence interval (C.I.) 2.17–42.18), elderly home residents (OR: 2.60; 95% C.I.
1.56–4.33), requirement of oxygen therapy during hospitalization (OR: 2.62; 95% C.I. 1.62–4.24), and
hemoglobin level <13.3 g/dL upon admission (OR: 2.43; 95% C.I. 1.16–5.12) were independent risk
factors associated with 1-year mortality in patients hospitalized for rhinovirus infection. Rhinovirus
infection in the adults was associated with significantly higher mortality and longer hospitalization
when compared with influenza virus infection. Institutionalized older adults were particularly at
risk. More stringent infection control among health care workers in elderly homes could lower the
infection rate before an effective vaccine and antiviral become available.
Int. J. Mol. Sci. 2017, 18, 259; doi:10.3390/ijms18020259 www.mdpi.com/journal/ijms
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1. Introduction
Human rhinoviruses (HRV) are RNA virus from the Picornaviridae family and are divided into
three species A, B, and C [1–4]. Currently, more than 100 distinct serotypes have been identified.
Every year, these viruses cause both upper and lower respiratory tract infections in young children
and adults during the spring and fall period in Hong Kong [5,6]. Clinical presentations varied from
asymptomatic infection, to upper respiratory symptoms including rhinorrhea, postnasal drip, and
cough, and to the more severe trachea-bronchitis and pneumonia, requiring hospitalization [1,7,8].
Older adults and immunocompromised patients were particularly at risk of developing severe infection
and bacterial co-infection, requiring prolonged hospitalization and treatment [8,9]. Patients with
underlying chronic obstructive pulmonary disease (COPD) and asthma are also at risk of developing
acute exacerbations [10,11]. HRV is predominantly transmitted via droplets or by indirect contact with
contaminated fomites. Major rhinovirus outbreaks in health care facilities have been reported [12–16].
Despite the clinical importance of HRV infection, the clinical characteristics and mortality risk
factors have not been well described. The objective of the current retrospective analysis on a prospective
cohort was to compare adult patients hospitalized for HRV infection with those hospitalized for
influenza infection during the same period and to identify independent risk factors associated with
mortality for HRV infection.
2. Results
Between 1 March 2014 and 28 February 2015, a total of 1946 patients were recruited consecutively
(Table 1). Of these, 728 patients were hospitalized for HRV infection, and 1218 patients were
hospitalized for influenza infection. Among those patients admitted for influenza infection, 76.5%
was H3N2, 3.8% was H1N1, 19.3% was B, and 0.4% was C. The overall mean age was 72.9 years
(Standard deviations (S.D.): 19.2 years) and 44.7% were male. Majority of the influenza cases (63.6%)
was admitted during the winter peak in January and February 2015 (Figure 1), with a smaller summer
peak (10.1%) in June and July 2014. Cases of HRV were admitted evenly throughout the year, with
fewer cases between June and August 2014.
Table 1. Baseline demographics and laboratory findings of patients hospitalized for rhinovirus infection
vs. influenza infection. (p-value < 0.05 highlighted in bold).
Baseline Demographics Rhinovirus (n = 728) %(Unless Stated)
Influenza (n = 1218) %
(Unless Stated) p-Value
Age; Mean (S.D.) 71.6 (20.2) 73.7 (18.6) 0.06
Male sex 44.6 44.7 0.97
Elderly home resident 31.3 23.5 <0.001
Comorbidity
Charlson comorbidity index; Mean (S.D.) 0.8 (0.8) 0.8 (0.9) 0.14
Pulmonary diseases 22.9 15.7 <0.001
Cardiovascular diseases 21.6 19.9 0.37
Stroke 9.5 13 0.02
Malignancy 7.6 6.2 0.22
Diabetes mellitus 26.4 27.7 0.53
Smoker 21.3 19.8 0.35
Influenza vaccination 8.4 9.2 0.54
Pneumococcal vaccination 8.1 12.2 0.06
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Table 1. Cont.
Baseline Demographics Rhinovirus (n = 728) %(Unless Stated)
Influenza (n = 1218) %
(Unless Stated) p-Value
Presenting Symptoms
Days of symptom onset to admission; Mean (S.D.) 2.8 (4.8) 2.4 (4.2) 0.10
Fever (>37.8) 42.2 65.6 <0.001
Cough 57 67.6 <0.001
Sputum production 53 49.6 0.15
Sore throat 5.1 14.4 <0.001
Chest wheezes 15.4 11.2 0.007
Rhinorrhea 6.6 11.2 0.001
Complications
Pneumonia 32.6 28 0.03
Cardiovascular 3.8 7.6 0.001
Sepsis 2.2 4.1 0.03
Treatment
Oxygen therapy 33.1 25.4 <0.001
Invasive ventilation 0.68 0.74 0.90
Non-invasive ventilation 2.6 3.1 0.52
Hospitalization days; Mean (S.D.) 8.7 (13) 6.8 (12) <0.001
Hospitalization frequency; Mean (S.D.) 2.2 (2.4) 1.9 (1.9) 0.36
ICU admission 1.8 2.4 0.38
Upon Admission with abnormal value
Hemoglobin (<13.3 g/dL) 75.4 69.7 0.01
Neutrophil (>7.42 × 109 /L) 42.3 26 <0.001
Lymphocyte (<1.06 × 109 /L) 1.8 0.9 0.11
Creatinine (>109 µmol/L) 25.5 27.5 0.37
ALT (>58 U/L) 6 5.7 0.76
AST (>38 U/L) 19.5 28.4 <0.001
Creatine kinase (>174 IU/L) 21.8 8.7 0.01
Mortality
30-day 9.6 7.1 0.04
90-day 14.2 10 0.006
1-year 17.2 11.7 0.004
Cause of death
Pneumonia 81.6 81.1 0.92
Stroke 3.2 3.5 0.89
Malignancy 10.4 12.7 0.56
Chronic renal failure 2.4 5.6 0.19
Acute myocardial infarction 4.8 2.8 0.66
Congestive heart failure 2.4 5.6 0.19
COPD 20.8 15.4 0.39
Other 1.6 4.2 0.21
Comparing the HRV group with the influenza group (Table 1), significantly more HRV patients
were elderly home residents and had chronic pulmonary diseases (p < 0.001), whereas more influenza
patients had previous stroke (p = 0.02); otherwise, there were no differences in the Charlson comorbidity
indexes between the two groups. More patients in the rhinovirus group presented with chest wheezes
(p = 0.007), developed pneumonia complication (p = 0.03), required oxygen therapy, and had a longer
hospitalization period (p < 0.001), whereas more patients in the influenza virus group presented with
fever (p < 0.001) and upper respiratory tract symptoms of cough (p < 0.001), sore throat (p < 0.001) and
rhinorrhea (p = 0.001), developed cardiovascular (p < 0.001) and sepsis complications (p = 0.03).
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Figure 1. Cases of rhinovirus and influenza hospitalized in Queen Mary Hospital between 1 March 2014
and 28 February 2015.
Comparing the laboratory findings upon admission between the HRV and influenza groups
(Table 1), the HRV group has a significantly higher proportion of patients with hemoglobin
<13.3 g/dL (p = 0.01), neutrophil count >7.42 × 109 /L (p < 0.001) and creatinine kinase >174 IU/L
(p = 0.01) compared with the influenza group, which has a significantly higher proportion of patients
with AST >38 IU/L (p < 0.001). Concerning the bacteriological findings, there were no differences in
the culture positive specimens between the two groups. Sputum culture was positive for Streptococcus
pneumoniae (1% vs. 0.5%; p = 0.22), Haemophilus influenzae (HRV vs. influenza) (2.1% vs. 1.9%;
p = 0.79), Staphylococcus aureus (1.5% vs. 1.1%; p = 0.49), Pseudomonas aeruginosa (2.2% vs. 2.1%;
p = 0.93), Klebsiella species (1% vs. 0.8%; p = 0.74), Acinetobacter baumannii (0.1% vs. 0.3%; p = 0.42), and
Moraxella catarrhalis (0.3% vs. 0.2%; p = 0.91). Blood culture was positive for Streptococcus pneumoniae
(0.3% vs. 0.2%; p = 0.6), Staphylococcus aureus (0.1% vs. 0.08%; p = 0.71), Proprionibacterium acnes
(0% vs. 0.2%; p = 0.27), Escherichia coli (0.2% vs. 0.1%; p = 0.61), Acinetobacter baumannii (0.1% vs. 0.2%;
p = 0.88), Moraxella catarrhalis (0.1% vs. 0%; p = 0.2), Morganella morganii (0% vs. 0.1%; p = 0.44), Proteus
species (0.1% vs. 0%; p = 0.2), Enterococcus faecalis (0.1% vs. 0%; p = 0.2), Bacteriodes species (0% vs. 0.1%;
p = 0.44), and Citrobacter freundii (0% vs. 0.1%; p = 0.44).
Comparing the radiological findings upon admission between the HRV and influenza groups,
majority of the patients (21.8%) in both groups presented with right lower zone opacity or consolidation
on chest radiograph taken upon admission. Significantly more patients in the HRV group presented
with right upper zone (5.9% vs. 2.4%), right middle zone (3.2% vs. 0.7%), left upper zone (3.3% vs.
0.2%), and bilateral upper zone (2.7% vs. 0.2%) opacity or consolidation (p < 0.001), whereas more
influenza patients presented with left lower zone (3.5% vs. 1.5%) or bilateral lower zone (3.4% vs.
0.7%) lesions (p < 0.001).
The 30-day (p = 0.04), the 90-day (p = 0.006) and 1-year (p = 0.004) mortality rate was significantly
higher in the HRV group than the influenza virus group (Table 1 and Figure 2). One hundred
and twenty-five patients (17.2%) in the HRV group succumbed by the end of the 1-year follow-up,
comparing to 143 patients (11.7%) in the influenza group. Majority of the HRV patients died of
pneumonia (81.6%), followed by COPD (20.8%), and malignancy (10.4%). A significant proportion of
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patients had more than one causes of death. There was no significant difference in the cause of death
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Figure 2. Kaplan–Meier survival curve of patients hospitalized for rhinovirus and influenza infection.
Comparing patients who succumbed with those who survived in the HRV group by univariate
analysis (Table 2), patients in the succumbed group were significantly older (p < 0.001) and more
patients were elderly home residents (p < 0.001). Succumbed patients had a higher Charlson
comorbidity index (p = 0.04) with more chronic pulmonary diseases (p = 0.008). Patients who survived
have significantly more upper respiratory tract symptoms including sore throat (p = 0.004) and
rhinorrhea (p = 0.001). Significantly more patients in the succumbed group developed pneumonia
(p < 0.001), cardiovascular (p = 0.008) and sepsis (p = 0.03) complications, required oxygen therapy
(p < 0.001), required non-invasive ventilation (p = 0.003) and had longer (p < 0.001) and more frequent
hospitalization (p = 0.02). Patients who succumbed also had, in a significantly higher proportion,
hemoglobin <13.3 g/dL (p = 0.001), neutrophil count >7.42 × 109 /L (p = 0.03), creatinine >109 µmol/L
(p = 0.03), and AST >38 IU/L (p = 0.003) compared with patients who survived.
Multivariate analysis (Table 3) demonstrated that intensive care unit admission (odds ratio
(OR): 9.56; 95% confidence interval (C.I.) 2.17–42.18), elderly home residents (OR: 2.60; 95% C.I.
1.56–4.33), the requirement of oxygen therapy during hospitalization (OR: 2.62; 95% C.I. 1.62–4.24),
and hemo lobin level <13.3 g/dL upon admission (OR: 2.43; 95% C.I. 1.16–5.12) were independent
risk factors associated with 1-year mortality in patients hospitalized for HRV infection. Rhinorrhea
was independently associated with lower 1-year mortality (OR: 0.31; 95% C.I. 0.11–0.86).
Int. J. Mol. Sci. 2017, 18, 259 6 of 10
Table 2. Univariate analysis of factors associated with 1-year mortality in patients hospitalized for
rhinovirus infection. (p-value < 0.05 highlighted in bold).
Baseline Demographics Survived (n = 603) %(Unless Stated)
Succumbed (n = 125) %
(Unless Stated) p-Value
Age; Mean (S.D.) 69.4 (20.7) 81.9 (13.6) <0.001
Male sex 45.4 40.8 0.34
Elderly home resident 25.2 60.8 <0.001
Comorbidity
Charlson comorbidity index; Mean (S.D.) 0.81 (0.81) 0.95 (0.76) 0.04
Pulmonary diseases 21.1 32 0.008
Cardiovascular diseases 21.2 23.2 0.63
Stroke 9.1 11.2 0.47
Malignancy 7.1 10.4 0.21
Diabetes mellitus 27 23.2 0.38
Smoker 20.7 24 0.42
Influenza vaccination 8.8 6.4 0.38
Pneumococcal vaccination 11.4 14.4 0.35
Presenting Symptoms
Days of symptom onset to admission;
Mean (S.D.) 2.8 (5) 2.7 (4) 0.69
Fever (>37.8) 41.5 45.6 0.39
Cough 55.7 63.2 0.12
Sputum production 48.1 56.8 0.08
Sore-throat 7.8 0.8 0.004
Chest wheezes 15.1 16.8 0.63
Rhinorrhea 15.6 4 0.001
Complications
Pneumonia 27.5 56.8 <0.001
Cardiovascular 3 8 0.008
Sepsis 1.7 4.8 0.03
Bacterial co-infection 1.0 2.4 0.20
Treatment
Oxygen therapy 27 62.4 <0.001
Invasive ventilation 0.5 1.6 0.17
Non-invasive ventilation 1.8 6.4 0.003
Hospitalization days; Mean (S.D.) 7.6 (11.1) 13.8 (18.6) <0.001
Hospitalization frequency; Mean (S.D.) 2 (2.2) 2.9 (3.4) 0.02
ICU admission 1.1 4.8 0.005
Upon Admission with abnormal value
Hemoglobin (<13.3 g/dL) 77.6 90.4 0.001
Neutrophil (>7.42 × 109 /L) 43 53.6 0.03
Lymphocyte (<1.06 × 109 /L) 2.1 0.8 0.37
Creatinine (>109 µmol/L) 25.4 35.2 0.03
ALT (>58 U/L) 6.1 8 0.41
AST (>38 U/L) 18.6 30.4 0.003
Creatine kinase (>174 IU/L) 9.1 9.6 0.99
Table 3. Multivariate analysis of independent risk factors associated with 1-year mortality in patients
hospitalized for rhinovirus infection.
Variable Odds Ratio 95% Confidence Interval p-Value
Rhinorrea 0.31 0.11–0.86 0.024
Elderly home resident 2.60 1.56–4.33 <0.001
ICU admission 9.56 2.17–42.18 0.003
Oxygen therapy 2.62 1.62–4.24 <0.001
Hemoglobin level <13.3 g/dL upon admission 2.43 1.16–5.12 0.019
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3. Discussion
We reported findings of the first retrospective cohort study comparing hospitalized patients with
HRV infection against those with influenza virus infection during the same period. Despite similar
baseline demographics and the Charlson comorbidity score, significantly more patients hospitalized
for HRV infection were elderly home residents, which was also one of the independent risk factors
associated with 1-year mortality. Major HRV outbreaks in health care facilities resulted in severe
infections, and death has been reported [12–16]. Household transmission of HRV infection was 1 case
per person among 17 siblings [17]. Droplet transmissions in a confined area such as elderly homes and
indirect contact with contaminated fomites by health care workers were the most significant culprit [18].
HRV can survive on environmental surfaces for several hours thereby facilitating transmission.
Compared to the influenza virus, HRV is a non-enveloped virus, which is difficult to disinfect and with
no vaccine and antiviral treatment. Studies have demonstrated that ethanol-containing disinfectant
were unable to remove HRV [19,20] and did not reduce HRV infection or related common cold illnesses.
Washing with soap and water was more efficient. Therefore, stringent infection control, such as regular
hand washing with soap, wearing of surgical mask, and regular cleansing of the air filters, should
reduce the risk of major outbreak among elderly home residents.
HRV infections are well known to be associated with acute exacerbation of chronic respiratory
disease including asthma, COPD, sinusitis, and otitis media [10,11,21]. It is the most common isolated
virus in acute exacerbation of COPD. Therefore, it was not surprising to find that patients hospitalized
with HRV infection had significantly more chronic pulmonary diseases when compared to patients
hospitalized for influenza infection. HRV patients are at a higher risk of developing pneumonia,
and upper respiratory symptoms were not as common as influenza infection. An in vivo study
demonstrated that HRV infection increased cytokine and chemokine levels, especially IL-6, which
may mediate lower airway symptoms during acute exacerbation of COPD [22]. HRV replication also
induces the production of interferon-γ inducible protein 10, which plays an important role in the
pathogenesis in COPD exacerbation. Apart from chronic lung diseases, patients with underlying
malignancy are also at risk of acquiring HRV infection [23]. Both HRV and influenza patients are at
risk of developing acute myocardial infarction and stroke complications [24].
It was interesting to demonstrate differences in radiological findings between patients infected
with the two viruses. Significantly more HRV patients presented with upper and middle zone lesions,
whereas influenza patients presented with more lower zone lesions. Such differences in distribution
could be related to the smaller size (50 nm) and lighter weight of the HRV when compared to the
influenza virus (80–120 nm). Besides, significantly more HRV patients had underlying pulmonary
diseases, which could affect the initial radiological presentation. The exact reasons required further
investigation. Similarly, there were significant differences in the various biochemical markers, including
lymphocyte count, haemoglobin, ALT, AST, and creatinine level, between the HRV and influenza
groups. Nevertheless, such differences were very small and the data has to be interpreted with caution.
Chronic pulmonary disease and bacterial co-infection in patients with HRV infection could explain
the lower hemoglobin level and higher neutrophil count upon admission. Bacterial co-infection also
worsened the FEV-1 in COPD patients [25]. The poor lung function coupled with the pneumonia
complications led to longer hospital stay and more frequent hospitalization. As a result, HRV
infection was associated with significantly higher 30-day, 90-day, and 1-year mortality rates than
influenza infection. It was also interesting to find that patients who survived after HRV infection
had significantly more common upper respiratory symptoms including rhinorrhea and sore throat
upon presentation. In contrast, succumbed patients presented with more prominent lower respiratory
symptoms including sputum production and subsequent pneumonia complication. This could be
explained by the upregulation of cell surface markers and activation of cytokine and chemokine in the
tracheobronchial tree, resulting in early activation of Toll-like receptor 3 (TLR3), thus establishing an
effective antiviral response in the upper airways, thereby preventing pneumonia development [26].
Int. J. Mol. Sci. 2017, 18, 259 8 of 10
Failure to eliminate the rhinovirus in the upper airway resulted in IL-6, IL-4, and IFN-γ production by
CD4 cells in the lower airway, causing airway hyperreactivity and lung inflammation [22].
Various anti-HRV agents have undergone clinical trials. Capsid-binding anti-HRV agent pleconaril
showed that early treatment exerted antiviral effects and reduced the duration of HRV cold [27].
Nevertheless, pleconaril has not been approved for clinical use due to potential drug interaction.
Another oral capsid-binding anti-HRV agent vapendavir showed dose-related antiviral effects with
significantly lower upper respiratory symptom scores early in the illness and less frequent HRV RNA
detection rate on Day 3 after treatment [28]. Intranasal recombinant interferon-α 2b was shown to be
effective in preventing HRV colds as post-exposure prophylaxis but lack treatment effect, whereas
inhaled interferon-β has demonstrated therapeutic efficacy in asthmatic patients [29]. Limited antigenic
cross-reactivity poses challenges in developing an effective HRV vaccine. Peptide immunogens and T
cell inducing vaccine strategies have the greatest potential in providing cross-reactivity against HRV
infection [30].
4. Materials and Methods
Consecutive patients aged ≥18 years with HRV or influenza infection admitted to the Queen
Mary Hospital from 1 March 2014 through 28 February 2015, over a one-year period, were enrolled into
a retrospective cohort study, which was approved by the Institutional Review Board of the University
of Hong Kong and Hospital Authority Hong Kong West Cluster (IRB reference number: UW 13-265,
date of approval 10 April 2013). HRV or influenza infection was confirmed by a positive test by reverse
transcription polymerase chain reaction (RT-PCR) of the respective virus on the nasopharyngeal
samples (NPS) taken from the patients upon admission [10]. All NPS on admission were assessed by
in-house multiplex PCR in the laboratory of the Department of Microbiology, University of Hong Kong,
for picornarvirus, EV71, and internal control (bovine viral diarrhea virus). Respiratory specimens were
also sent to the Department of Health for detection of influenza A, B, and C viruses, parainfluenza
viruses 1, 2, 3, and 4, respiratory syncytial viruses, and adenovirus by three other multiplex PCRs.
Bacterial culture in sputum or blood was performed when clinically indicated. Clinical findings
including history and physical examination, oximetric measurement, hematological, biochemical,
radiological, and microbiological investigation results were retrieved from the clinical management
system (CMS) and entered into a predesigned database. Laboratory findings of hemoglobin
<13.3 g/dL, neutrophil count >7.42 × 109 /L, lymphocyte count <1.06 × 109 /L, creatinine
>109 µmol/L, alaninine transaminase (ALT) >58 U/L, aspartate aminotransferase (AST) >38 U/L,
and creatinine kinase >174 IU/L upon admission were defined as abnormal value. Requirement
of oxygen therapy, invasive and non-invasive ventilation, intensive care unit (ICU) admission, and
hospitalization days and frequency were also assessed.
Comorbidity was categorized into chronic pulmonary diseases, cardiovascular diseases, stroke,
malignancy, and diabetes mellitus. Chronic pulmonary diseases include COPD, asthma, and
bronchiectasis, whereas cardiovascular diseases include coronary artery disease, valvular heart disease,
and congestive heart failure. The chest radiograph findings have been assessed by the clinician
in-charge. Patients were followed up from admission for a period of at least 3 months and up to
15 months.
Statistical Analysis
Clinical and laboratory parameters were compared by γ2 for categorical variables and
Mann–Whitney U-test for continuous variables. Significant risk factors for death were further analyzed
by Cox regressions to identify the independent risk factors. A log-rank test was used to evaluate the
overall survival over a period of 1-year after admission. IBM SPSS Statistics 10.0 was used for statistical
computation. A p-value < 0.05 was considered to represent significant difference.
Int. J. Mol. Sci. 2017, 18, 259 9 of 10
5. Conclusions
Limitations of this study include its retrospective nature, and we did not have data on the HRV
serotypes in our cohort. In conclusion, HRV infection caused significant mortality and morbidity,
especially among those who lived in elderly homes. Infection control measures could reduce HRV
infection in these at risk subjects.
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